Home › Quitting Smoking (Tobacco Use Disorder) › NCT06688539
E-cigarette Cessation in Adults Who Co-use Cannabis
A Prospective Trial of Varenicline and Incentives for E-cigarette Cessation in Adults Who Co-use Cannabis
Who can join
Ages 18 to 40 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Between the ages of 18 and 40 years old * Use e-cigarettes daily or near daily in the past month * Must submit a positive instant-read urine cotinine test at screening (≥ 200 ng/ml) * Be interested in quitting use of e-cigarettes * Must be willing to take varenicline for the standard 12-week course of treatment * Self-reported use of cannabis on at least 10 out of the past 30 days or must submit a positive qualitative urinary cannabinoid test at screening (\> 50 ng/ml) Exclusion Criteria: * Any serious or unstable medical/psychiatric disorder (including severe substance use disorders, other than cannabis or tobacco use disorders) in the past three months that may interfere with study performance * Use of cigarettes on 10+ days in the past 30 * Currently pregnant or breastfeeding * Current use of medications with smoking cessation efficacy * Use of any medications that would interfere with varenicline
About the study
The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.
What is being tested
- Varenicline Pill (drug)
- Contingency management (behavioral)
- Counseling (behavioral)
Sponsor: Medical University of South Carolina · Participants: 105 · Started: Feb 19, 2025
Contact the study team
- Elizabeth Chapman, MA, LPC, LAC, AADC · Phone: 864.898.2992
Official record on ClinicalTrials.gov — NCT06688539
Locations in the U.S.
| South Carolina | MUSC Charleston, Charleston MUSC Lancaster, Lancaster Behavioral Health Services of Pickens County, Pickens |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.